The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

A retired investigator for the state chiropractic board tells us this is the one case that he could not forget -- the one that got away, in his words. And he is frustrated that the board has been ...

UCSD and the Department of Veterans Affairs Collaboration CARLSBAD, CA, UNITED STATES, December 31, 2025 /EINPresswire.com/ — AVACEN Medical announced today that Dr. Francisco Cidral, ND, PhD’s ...

Transplanting bacteria from the feces of healthy people into the guts of mice and patients with fibromyalgia successfully reduced pain levels, opening up a potentinal avenue for new microbe-derived ...

Paul Whitcomb, a South Lake Tahoe chiropractor, believes he has found a cure for fibromyalgia, a disease that hypersensitizes the nervous system and causes debilitating pain in millions of Americans, ...

A study conducted by British researchers found that patients with fibromyalgia (FM) reported improved quality of life following use of medical cannabis pro | Health And Medicine ...